N/A
Completed N=56
Impact of Vitamin D Therapies on Chronic Kidney Disease
Chronic Kidney Disease (CKD) · End-stage Renal Disease (ESRD)
Source: ClinicalTrials.gov NCT01222234 ↗
Enrolled (actual)
56
Serious AEs
0.0%
Results posted
May 2016
Primary outcomePrimary: Monocyte Protein Expression — 34110; 38540; 1359; 1360 relative fluorescence units
Summary
This investigation will consist of a prospective study utilizing two separate populations of patients with 25(OH)D deficiency, one population with chronic kidney disease (CKD) and one with normal renal function.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Monocyte Protein Expression |
34110; 38540; 1359; 1360; 2799; 3468 | — |
| PRIMARY Change in 24,25(OH)2D Levels in CKD vs. Non-CKD Subjects Receiving Cholecalciferol |
1.59; 3.59 | — |
Eligibility Criteria
Inclusion Criteria
- Chronic kidney disease w/GFR 75pg/mL
Exclusion Criteria
- Active infection
- Recent hospitalization for acute illness (within last month)
- Refusal to study participation
- History of chronic inflammatory disease process (i.e. inflammatory bowel, rheumatoid arthritis, SLE, etc.)
- Allergy to cholecalciferol or calcitriol
- History of parathyroidectomy
- Functional renal transplant within 5 years
- Current treatment with immunosuppressant medications
- Noncompliance with prescribed medications
Data sourced from ClinicalTrials.gov (NCT01222234). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.